X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
breast neoplasms - drug therapy (4) 4
breast neoplasms - pathology (4) 4
disease-free survival (4) 4
female (4) 4
humans (4) 4
oncology (4) 4
treatment outcome (4) 4
aged (3) 3
breast cancer (3) 3
cancer therapies (3) 3
chemotherapy (3) 3
hematology, oncology and palliative medicine (3) 3
index medicus (3) 3
middle aged (3) 3
adult (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
biomarkers, tumor - analysis (2) 2
breast neoplasms - genetics (2) 2
breast neoplasms - mortality (2) 2
cancer (2) 2
care and treatment (2) 2
cell cycle (2) 2
clinical trials (2) 2
double-blind method (2) 2
drug administration schedule (2) 2
endocrine therapy (2) 2
metastasis (2) 2
neoplasm metastasis (2) 2
oncology, experimental (2) 2
piperazines - administration & dosage (2) 2
proportional hazards models (2) 2
pyridines - administration & dosage (2) 2
receptor, erbb-2 - analysis (2) 2
receptor, erbb-2 - genetics (2) 2
receptors, estrogen - analysis (2) 2
research (2) 2
resistance (2) 2
survival (2) 2
survival analysis (2) 2
therapy (2) 2
trastuzumab (2) 2
womens health (2) 2
administration, oral (1) 1
aged, 80 and over (1) 1
analysis (1) 1
anti-her2 monoclonal-antibody (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal - adverse effects (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antibodies, monoclonal, humanized (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
aromatase inhibitors (1) 1
aromatase inhibitors - administration & dosage (1) 1
biomarkers, tumor - blood (1) 1
biomarkers, tumor - genetics (1) 1
blood (1) 1
breast neoplasms - blood (1) 1
breast neoplasms - chemistry (1) 1
breast neoplasms - enzymology (1) 1
cardiovascular disease (1) 1
cell-cycle (1) 1
cells (1) 1
class i phosphatidylinositol 3-kinases (1) 1
clinical outcomes (1) 1
clinical trials, phase ii as topic (1) 1
clinical trials, phase iii as topic (1) 1
combination (1) 1
combined modality therapy (1) 1
cyclin d1 - genetics (1) 1
cyclin-dependent kinase 4 - antagonists & inhibitors (1) 1
cyclin-dependent kinase 4 - metabolism (1) 1
cyclin-dependent kinase 6 - antagonists & inhibitors (1) 1
cyclin-dependent kinase 6 - metabolism (1) 1
cyclin-dependent kinase inhibitor p16 - genetics (1) 1
diabetes (1) 1
disease progression (1) 1
docetaxel (1) 1
dose-response relationship, drug (1) 1
drug dosages (1) 1
embolisms (1) 1
epidemiology (1) 1
estradiol - administration & dosage (1) 1
estradiol - analogs & derivatives (1) 1
estrogen (1) 1
estrogen-receptor (1) 1
europe (1) 1
everolimus (1) 1
exemestane (1) 1
expression (1) 1
fever - chemically induced (1) 1
first-line therapy (1) 1
fish (1) 1
fractures (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 816 - 829
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 4, pp. 425 - 439
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 25 - 35
Summary Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EXEMESTANE | ONCOLOGY | CELL-CYCLE | POSTMENOPAUSAL WOMEN | HER2 | PLUS | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Triazoles - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Molecular Targeted Therapy | North America | Nitriles - administration & dosage | Breast Neoplasms - enzymology | Time Factors | Postmenopause | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Republic of Korea | Aromatase Inhibitors - administration & dosage | Pyridines - administration & dosage | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Europe | Proportional Hazards Models | Cyclin-Dependent Kinase Inhibitor p16 - genetics | Treatment Outcome | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Cyclin D1 - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | South Africa | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Care and treatment | Oncology, Experimental | Estrogen | Breast cancer | Research | Antineoplastic agents | Phosphotransferases | Cancer
Journal Article
Oncology, ISSN 0030-2414, 2001, Volume 61, Issue 2, pp. 37 - 42
Journal Article
Austin American Statesman, 01/2001
  It probably won't be the happiest of Saturday nights, but the doubly-mopey bill of Son Volt/Uncle Tupelo frontman Jay Farrar with Varnaline's Anders Parker... 
Newspaper Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.